Christopher Uhde: Hi, there. Christopher Uhde, SEB. So I have a question on SUPERNOVA and the COVID antibody update in general. So obviously that so — I saw that the time line seems to be reiterated. But we’re moving toward the latter part of the half not so much time to get it to patients before the end of the year. So, perhaps could you just remind us a little bit about the factors determining the time from topline to EUA? And can you also talk a little bit about how you’re planning to brand it? It seems that it won’t be — have you shelled, but I guess that has advantages and disadvantages. So perhaps you could talk about that. And then in terms of Fasenra, the growth levers going forward and also thinking about — I thought GSK has an ultra extended half-life IL-5. So what are your thoughts around competition? Thank you.
Pascal Soriot: Thank you, Christopher. Aradhana, do you want to take the first one? And Ruud, do you take the next one?
Aradhana Sarin: Thanks. Christopher, thanks for the question and also thanks for your continuous interest in this area. So, we are continue to rapidly advance AZD3152, which is a new long-acting monoclonal antibodies for prevention and treatment of COVID-19 for immunocompromised patients. And I’m pleased to say that SUPERNOVA trial is on track. As you are mentioning, we did updated the trial and that was a result of the trial design. And that was a result of the consultation and agreement with the FDA, because we believe that is the fastest way how to achieve emergency approval for the patients in US. And currently, the trial is updated with the sub-study or immunobridging data. As a reminder, this is a President-study design and will allow us to have the data late this year.
Obviously, as we are moving from the beginning with the 8th phase, we will do our best to deliver AZD3152 to the immunocompromised patients in US by end of this year. Equally, we are continuing the SUPERNOVA trial with efficacy endpoint, and we believe that efficacy data readout will happen in the first quarter of next year. That will allow us to have the approval globally outside of US. On your branding question, thanks for that. I do agree that not having shelled the brand name for our new next-generation monoclonal antibody has its good and bad side. We are currently in discussion both with FDA and EMA, and we will provide the update on the brand name as soon as we get agreement from those agencies.
Ruud Dobber: Okay. Thank you so much. Chris, quickly, the growth drivers for Fasenra in the foreseeable future. There are three big ones. First of all, by far, the biggest one is still biopenetration is at the low side for biologics in severe uncontrolled asthma, depending on where you are, it’s everything between 15% and 25%. So there’s still a huge room to maneuver in a positive way. The second one, what I said in my remarks is that China is an important growth driver. We have filed in China based on the outstanding miracle trial. So hopefully, next year, we will see the results. And last but not least, later this year, we will see the outcome of Fasenra and EGPA. It’s another very important growth driver for the brand. So all in all, we truly believe that there’s still a very bright future for Fasenra.
Quickly, your remark about long-acting, of course, we have our own Fasenra is every 2 months. So we don’t foresee a major impact of our molecules. The class is very competitive. But once again, bio penetration across the board is still at a very low level. So more competitors will also make — we grow the market in an acceptable and good way.
Pascal Soriot: Thank you, Ruud. James Gordon, JP Morgan. James, over to you.
